Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

Sven De Vos, André Goy, Shaker R. Dakhil, Mansoor N. Saleh, Peter McLaughlin, Robert Belt, Christopher R. Flowers, Mark Knapp, Lowell Hart, Dipti Patel-Donnelly, Martha Glenn, Stephanie A. Gregory, Charles Holladay, Tracy Zhang, Anthony L. Boral

Research output: Contribution to journal › Article › peer-review

87 Scopus citations

Fingerprint

Dive into the research topics of 'Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences